Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28095
Title: Bronchodilator reversibility as a diagnostic test for adult asthma: findings from the population-based Tasmanian Longitudinal Health Study.
Austin Authors: Tan, Daniel J;Lodge, Caroline J;Lowe, Adrian J;Bui, Dinh S;Bowatte, Gayan;Johns, David P;Hamilton, Garun S;Thomas, Paul S;Abramson, Michael J;Walters, E Haydn;Perret, Jennifer L ;Dharmage, Shyamali C
Affiliation: Institute for Breathing and Sleep
School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia..
School of Medicine, University of Tasmania, Hobart, Tasmania, Australia..
Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia..
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia..
Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia..
Dept of Basic Sciences, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka..
National Institute of Fundamental Studies, Kandy, Sri Lanka..
Prince of Wales' Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia..
Issue Date: 8-Feb-2021
Date: 2021-01
Publication information: ERJ open research 2021; 7(1): 00042-2020
Abstract: Bronchodilator reversibility (BDR) is often used as a diagnostic test for adult asthma. However, there has been limited assessment of its diagnostic utility. We aimed to determine the discriminatory accuracy of common BDR cut-offs in the context of current asthma and asthma-COPD overlap (ACO) in a middle-aged community sample. The Tasmanian Longitudinal Health Study is a population-based cohort first studied in 1968 (n=8583). In 2012, participants completed respiratory questionnaires and spirometry (n=3609; mean age 53 years). Receiver operating characteristic (ROC) curves were fitted for current asthma and ACO using continuous BDR measurements. Diagnostic parameters were calculated for different categorical cut-offs. Area under the ROC curve (AUC) was highest when BDR was expressed as change in forced expiratory volume in 1 s (FEV1) as a percentage of initial FEV1, as compared with predicted FEV1. The corresponding AUC was 59% (95% CI 54-64%) for current asthma and 87% (95% CI 81-93%) for ACO. Of the categorical cut-offs examined, the European Respiratory Society/American Thoracic Society threshold (≥12% from baseline and ≥200 mL) was assessed as providing the best balance between positive and negative likelihood ratios (LR+ and LR-, respectively), with corresponding sensitivities and specificities of 9% and 97%, respectively, for current asthma (LR+ 3.26, LR- 0.93), and 47% and 97%, respectively, for ACO (LR+ 16.05, LR- 0.55). With a threshold of ≥12% and ≥200 mL from baseline, a positive BDR test provided a clinically meaningful change in the post-test probability of disease, whereas a negative test did not. BDR was more useful as a diagnostic test in those with co-existent post-bronchodilator airflow obstruction (ACO).
URI: https://ahro.austin.org.au/austinjspui/handle/1/28095
DOI: 10.1183/23120541.00042-2020
ORCID: 0000-0002-9954-0538
0000-0001-7034-0615
Journal: ERJ open research
PubMed URL: 33585659
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/33585659/
ISSN: 2312-0541
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on Nov 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.